Yale Scientists Reveal Molecular Pathway for Smarter Breast Cancer Drugs
New research at Yale has revealed major differences in aggressive types of breast cancer, and the potential for smarter treatments for patients. Triple-negative breast cancer, which has a low survival rate and a lack of helpful molecular biomarkers — specific proteins that signal the presence of disease — is among the most aggressive breast cancer subtypes.Source: Yale West Campus News
Yale Cancer Center Study Shows Immunotherapy Prior to Surgery May Help Destroy High-Risk Breast Cancer
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Geneticist Sidi Chen Receives Large Award Which Will Further His Breast Cancer Work
This Department of Defense award goes to the “best and brightest in their fields,” and recognizes “creative and innovative individuals.” Investigators are chosen for their ability “to go beyond conventional thinking” in their respective areas of expertise.
Sentinel Lymph Node Biopsy Provides no Benefit for Stage Zero Breast Cancer, Yale School of Public Health Study Finds
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS), gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.
Too Young to Screen: Breast Cancer in Younger Women
“Although breast cancer is most commonly diagnosed in postmenopausal women, it can happen in young women, too,” says Brigid Killelea, MD, chief of breast surgery at Yale Medicine. “I have patients who were diagnosed in their 20s.”Source: Yale Medicine
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.
Improving Breast Cancer Outcomes for African Women
For eight days in early June, Melissa Durand, MD, volunteered at the second-largest teaching hospital in Ghana, West Africa. Decades earlier, mammography technologist Judith Abaidoo of Yale New Haven Hospital’s Shoreline Medical Center became one of the first women to perform mammograms in Ghana, where the five-year breast cancer survival rate is estimated to be only 25%.